Expertise in
4
conditions

Peter W. Szlosarek

Charterhouse Square, 
London, ENG, GB 
Expertise in
4
conditions
Charterhouse Square, 
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Peter Szlosarek practices in London, United Kingdom. Mr. Szlosarek is highly rated in 4 conditions, according to our data. His top areas of expertise are Mesothelioma, Uveal Melanoma, Metastatic Uveal Melanoma, and Melanoma.

His clinical research consists of co-authoring 54 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Charterhouse Square, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma
A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma
Enrollment Status: Completed
Publish Date: August 24, 2022
Intervention Type: Drug
Study Drugs: Pembrolizumab, Gemcitabine, Vinorelbine
Study Phase: Phase 3
A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function
A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function
Enrollment Status: Completed
Publish Date: April 09, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

54 Total Publications

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.
Journal: Nature communications
Published: October 11, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Szlosarek's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile